BCDA Profile
BioCardia, Inc., a clinical-stage regenerative medicine company, specializes in developing cellular and cell-derived therapies aimed at treating cardiovascular and pulmonary diseases. The company’s primary focus is on advancing its lead therapeutic candidate, the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. This system represents a significant innovation in regenerative medicine, leveraging the potential of cellular therapies to improve heart function and overall patient outcomes.
BioCardia is also at the forefront of developing an allogeneic cell therapy platform, which includes an investigational treatment using culture-expanded bone marrow-derived mesenchymal cells. This therapy is currently in Phase I/II trials and targets ischemic systolic heart failure, offering a promising approach to managing this challenging condition. The company’s research extends to pulmonary diseases, reflecting its broad commitment to addressing major health issues through advanced cellular therapies.
In addition to its core therapeutic products, BioCardia offers specialized delivery systems to enhance the efficacy of its treatments. The Helix biotherapeutic delivery system, for instance, utilizes a penetrating helical needle to deliver therapeutics directly into the heart muscle. Complementing this is the Morph deflectable guide and sheath system, designed to improve precision in therapeutic delivery. These innovative tools support BioCardia’s mission to enhance treatment outcomes and patient safety.
BioCardia maintains a collaborative partnership with CellProthera SAS to advance ProtheraCytes, a novel therapy for acute myocardial infarction. This collaboration underscores BioCardia’s strategic approach to leveraging external expertise and resources to further its therapeutic goals. Founded and headquartered in Sunnyvale, California, BioCardia continues to drive forward its mission to revolutionize the treatment of cardiovascular and pulmonary diseases through cutting-edge regenerative medicine.
|
